Log in
Enquire now
‌

US Patent 11986537 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Patent 11986537 was granted and assigned to Dyne Therapeutics on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Dyne Therapeutics
Dyne Therapeutics
0
Current Assignee
Dyne Therapeutics
Dyne Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119865370
Patent Inventor Names
Timothy Weeden0
Cody A. Desjardins0
John Najim0
Mohammed T. Qatanani0
Brendan Quinn0
Romesh R. Subramanian0
Date of Patent
May 21, 2024
0
Patent Application Number
183496310
Date Filed
July 10, 2023
0
Patent Citations
‌
US Patent 7973015 Induction of exon skipping in eukaryotic cells
0
‌
US Patent 8084601 Oligomers
0
‌
US Patent 8232384 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
0
‌
US Patent 8324371 Oligomers
0
‌
US Patent 8361979 Means and method for inducing exon-skipping
0
‌
US Patent 8455636 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
0
‌
US Patent 8486907 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
0
‌
US Patent 8524880 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
0
...
Patent Citations Received
‌
US Patent 12102687 Muscle targeting complexes and uses thereof for treating myotonic dystrophy
0
‌
US Patent 12128109 Muscle targeting complexes and formulations for treating dystrophinopathies
0
Patent Primary Examiner
‌
Sheela J. Huff
0
CPC Code
‌
A61K 47/6849
0
‌
A61K 47/6807
0
‌
A61K 47/6889
0
‌
A61P 21/00
0
Patent abstract

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11986537 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.